This page preserves the issue as published. It is not overwritten when the next issue appears on the current Weekly page. Where a development below has since changed, the change is recorded as a dated correction rather than a silent edit.
IN FORCE01 · California
California AI Transparency Act is now operative
· Bus. & Prof. Code ch. 25 (SB 942, as amended by AB 853)
Chapter 25 became operative August 2, 2026. AB 853 moved the original January 1, 2026 date and added later phases. Covered providers — producers of a publicly accessible generative AI system with more than one million monthly visitors or users in California — must make a free AI detection tool available, offer a manifest disclosure option, and embed latent disclosures in AI-generated image, video and audio content. Text is not covered by the disclosure duties. Large online platform and GenAI hosting duties begin January 1, 2027; capture device manufacturer duties January 1, 2028.
Why it matters here. Health systems and clinical vendors that generate synthetic patient-facing media, and any practice deploying a consumer-facing generative tool, need to know whether they are a covered provider or merely a deployer. This is a content-provenance statute, not a clinical-safety statute, and must not be cited as if it regulates diagnostic AI.
EU AI Act Article 50 transparency obligations now apply
· Regulation (EU) 2024/1689, Art. 50
Article 50 applies from 2 August 2026. It requires providers and deployers to disclose direct interaction with an AI system, mark AI-generated or manipulated content in machine-readable form, notify individuals exposed to emotion recognition or biometric categorisation, and label deep fakes and AI-generated text published on matters of public interest. The Commission adopted final implementation guidelines on 20 July 2026; those guidelines are non-binding, and only the Court of Justice can give an authoritative interpretation. Content generated before 2 August 2026 does not have to be labelled retroactively.
Why it matters here. This is the closest international analogue to the California act, and the two took effect on the same day by design. Any comparison must keep the difference visible: Article 50 also covers interaction disclosure and emotion recognition, and it reaches non-EU providers whose output is used in the EU.
CMS placed the rule on public display July 14, 2026 and published it in the Federal Register July 16, 2026. The comment period closes at close of business September 14, 2026, and finalized policies would generally take effect January 1, 2027. The one-year 2.50% conversion-factor increase provided for CY 2026 does not carry into CY 2027. CMS proposes that where a separately identifiable office or outpatient E/M visit is furnished on the same day as a 0-, 10- or 90-day global procedure, the most expensive service is paid at 100% and other same-day surgical procedures or E/M visits at 50%. The rule proposes work and practice-expense RVU changes across more than fifty code families and carries requests for information on redesigning primary care payment and on alternatives to the CPT and RUC valuation process.
Why it matters here. This is a dossier, not a single article: payment, MIPS and value-based care, primary care redesign, telehealth and remote monitoring each move separately. The comment deadline is the only date on this page a practice can still act on directly.
CMS-0062-P would extend electronic prior authorization to drugs
· CMS-0062-P, Interoperability Standards and Prior Authorization for Drugs
The rule was published in the Federal Register on April 14, 2026 and the comment period closed June 15, 2026. It is proposed, not final. CMS-0057-F built the prior-authorization API infrastructure for non-drug items and services and deliberately excluded drugs; CMS-0062-P would extend electronic prior authorization, shortened decision timeframes and public reporting to drugs under both the medical and pharmacy benefit, require impacted payers to report interoperability API endpoints and usage metrics to CMS, and adopt certain HL7 FHIR standards under HIPAA Administrative Simplification. Most proposed provisions carry an October 1, 2027 compliance date.
Why it matters here. A correction to a widely repeated summary: this rule did not issue in July 2026, and its comment period is not open. Any KPSGILL page describing it must say proposed, must not present the October 2027 dates as current duties, and must be revised when a final rule issues.
ADMINISTRATIVE CHANGE05 · United States — HRSA / NPDB
NPDB merges One-Time Query and Continuous Query into NPDB Query
· National Practitioner Data Bank service change
On December 4, 2026 the NPDB will release NPDB Query, merging Individual One-Time Query and Continuous Query. Existing Continuous Query enrollments transfer automatically and require no action. Organizations still relying on One-Time Query need a transition plan; since March 13, 2026 they have been able to export a file of One-Time Query subjects and import it into Continuous Query as new enrollments, with a validation report identifying invalid, incomplete or duplicate subjects. Since July 2026 enrollment duration is selectable from one day to twelve months, a cancelled enrollment can be resumed within the enrollment period, and an enrollment can be ended immediately after the initial response completes.
Why it matters here. Credentialing offices that still run One-Time queries at recredentialing intervals are the ones affected. The change is operational rather than legal — what the NPDB reports, and a practitioner’s dispute rights, are unchanged — and should not be described as a change to reportable events.
DHCS issued an updated regulatory provider bulletin, effective July 23, 2026, restating that clinicians who order, refer or prescribe for Medi-Cal members must be enrolled in Medi-Cal under their individual Type 1 NPI. Medicare enrollment alone, and managed-care plan affiliation alone, do not satisfy the requirement; claims associated with an unenrolled ORP NPI can be denied. Medi-Cal Rx had set June 26, 2026 as the date it would begin denying pharmacy claims and prior authorizations for unenrolled prescribers. As of mid-August 2026 the California Medical Association reports that DHCS has moved toward phased implementation and has not announced a new enforcement date.
Why it matters here. The underlying obligation is long-standing federal and state law; what is genuinely unsettled is the enforcement calendar. A physician-facing article must not state a single hard deadline. The practical action — verify individual Type 1 NPI enrollment status in PAVE now — is unaffected by the date question.
These developments were raised in editorial review but were not confirmed against a primary source in this pass. They are listed so the queue is visible. Nothing here may be moved into an article, a card above, or structured data until its primary source has been read and cited.
Unverified tracking queue as of August 15, 2026
Jurisdiction
Reported development
Verification status
California
Medical Board of California quarterly Board and committee meetings reported for August 19–21, 2026
Agenda and meeting notice not verified to the Board’s own publication this turn.
California
Proposition 35 supplemental payment increases for dates of service July 1–December 31, 2026, reported as contingent on federal approval of SPA 26-0029
Neither the payment schedule nor the SPA status verified to DHCS or CMS this turn. Would publish labelled PENDING FEDERAL APPROVAL.
California
DMHC July 2026 enforcement against a health plan for grievance-resolution violations
Matter numbers, statutes cited and penalty amounts not verified to the DMHC enforcement action database this turn.
United States
CMS-2452-P health-care-related tax restrictions, reported July 21, 2026 with comments due September 21
Not verified to the Federal Register this turn.
United States
HHS-OIG findings on Medicare Advantage prior-authorization denials for post-acute admissions
Report numbers and denial-rate figures not verified to OIG this turn.
United States
FDA TEMPO Digital Health Devices Pilot first participant and its link to the CMS ACCESS model
Not verified to FDA this turn.
United States
FDA public meeting on MDUFA VI user-fee recommendations for FY 2028–2032
Not verified to FDA this turn.
United States
FDA approval of an oral PCSK9 inhibitor and other recent approvals
Approval letters and labelling not verified this turn. Clinical claims require label-level verification before any patient-facing page.
United States
2026 federal health-care fraud takedown — defendant counts and alleged loss figures
Not verified to a Department of Justice release or charging documents this turn. Charges are allegations; no page may imply guilt.